Biotechnology executive passionate about transforming innovation to benefit patients.
CEO of Dimerix Limited
Kathy is currently CEO of Dimerix Limited, an ASX listed drug development company focussed on developing a treatment for chronic kidney disease.
Kathy has built her career by combining her interests in and passion for science, intellectual property/ legal protection of inventions and translation of inventions into products, particularly in human healthcare. Her background includes undergraduate and post graduate degrees in science, qualifications and private practice experience as a Patent Attorney, and product development experience in three ASX listed biotechnology company’s prior to Dimerix. These create a blend of skills well suited to tackling human healthcare needs in a commercial context.
Kathy enjoys the opportunity to help PhD candidates starting their journey in industry through the Industry Mentoring Network in STEM (IMNIS) program.